
Novavax (NVAX) Stock Forecast & Price Target
Novavax (NVAX) Analyst Ratings
Bulls say
Novavax is showing positive signs of growth, with its promising vaccine technology and strong partnerships with other companies like Sanofi and Pfizer. The company's focus on preventative measures for a wide range of diseases highlights its potential for long-term success in the industry. Additionally, the recent deals and significant milestone payments from Pfizer further demonstrate the value and potential of Novavax's products. Although there are risks involved in the competitive vaccine market, Novavax's strong market share projections and solid financial performance make it a promising investment opportunity.
Bears say
Novavax is a commercial-stage vaccine company with its own in-house R&D business and partnerships with Sanofi and other companies. However, concerns about a declining U.S. COVID-19 vaccine market and a potentially differentiated tolerability profile for Nuvaxovid could impact the company's future revenues and profits. In addition, there are potential risks to the downside, including failure to successfully develop a combo vaccine and negative regulatory developments. These factors contribute to a negative outlook on Novavax's stock.
This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.
Novavax (NVAX) Analyst Forecast & Price Prediction
Start investing in Novavax (NVAX)
Order type
Buy in
Order amount
Est. shares
0 shares